First Header Logo Second Header Logo

Connection

Steven Feldman to Anti-Inflammatory Agents

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about Anti-Inflammatory Agents.
Steven Feldman
Connection Strength
10.504
Anti-Inflammatory Agents
  1. Okwundu N, Cardwell LA, Cline AE, Richardson IM, Feldman SR. Adherence to topical treatment can improve treatment-resistant moderate psoriasis. Cutis. 2020 Feb; 105(2):89-91;E2;E3.
    View in: PubMed
    Score: 0.654
  2. Wu JJ, Lu M, Veverka KA, Smulders M, Papademetriou E, Yu J, Feldman SR. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. J Dermatolog Treat. 2019 Aug; 30(5):446-453.
    View in: PubMed
    Score: 0.605
  3. Hogue L, Cardwell LA, Roach C, Felix KH, Oussedik E, Richardson I, Feldman SR. Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray. J Cutan Med Surg. 2019 Mar/Apr; 23(2):157-163.
    View in: PubMed
    Score: 0.605
  4. Curry ZA, Johnson MC, Unrue EL, Feldman SR. Caregiver willingness to treat atopic dermatitis is not much improved by anchoring. J Dermatolog Treat. 2019 Aug; 30(5):471-474.
    View in: PubMed
    Score: 0.603
  5. Howell ST, Cardwell LA, Feldman SR. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. Ann Pharmacother. 2018 04; 52(4):380-387.
    View in: PubMed
    Score: 0.561
  6. Snyder A, Farhangian M, Feldman SR. A review of patient adherence to topical therapies for treatment of atopic dermatitis. Cutis. 2015 Dec; 96(6):397-401.
    View in: PubMed
    Score: 0.490
  7. Aslam I, Sandoval LF, Feldman SR. What's new in the topical treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol. 2014 Oct; 14(5):436-50.
    View in: PubMed
    Score: 0.452
  8. Feldman SR, Huang WW, Huynh TT. Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease. J Manag Care Spec Pharm. 2014 Jun; 20(6):623-9.
    View in: PubMed
    Score: 0.441
  9. Semble AL, Davis SA, Feldman SR. Lack of information in current guidelines regarding systemic corticosteroids in inflammatory diseases. Dermatol Online J. 2014 Mar 17; 20(3).
    View in: PubMed
    Score: 0.435
  10. Davis SA, Feldman SR. Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials. JAMA Dermatol. 2013 Apr; 149(4):490-1.
    View in: PubMed
    Score: 0.407
  11. Shah A, O'Neill J, Feldman SR. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series. J Drugs Dermatol. 2010 Dec; 9(12):1491-4.
    View in: PubMed
    Score: 0.346
  12. Uhlenhake EE, Feldman SR. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. Expert Opin Biol Ther. 2010 Jul; 10(7):1105-12.
    View in: PubMed
    Score: 0.336
  13. Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis. 2009 Oct; 84(4 Suppl):25-32.
    View in: PubMed
    Score: 0.319
  14. Kosari P, Feldman SR. Case report: Fluocinonide-induced perioral dermatitis in a patient with psoriasis. Dermatol Online J. 2009 Mar 15; 15(3):15.
    View in: PubMed
    Score: 0.308
  15. Thomas K, Yelverton CB, Yentzer BA, Balkrishnan R, Fleischer AB, Feldman SR. The cost-effectiveness of rosacea treatments. J Dermatolog Treat. 2009; 20(2):72-5.
    View in: PubMed
    Score: 0.303
  16. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009; 10(6):397-406.
    View in: PubMed
    Score: 0.303
  17. Brown KL, Krejci-Manwaring J, Tusa MG, Camacho F, Fleischer AB, Balkrishnan R, Feldman SR. Poor compliance with topical corticosteroids for atopic dermatitis despite severe disease. Dermatol Online J. 2008 Sep 15; 14(9):13.
    View in: PubMed
    Score: 0.297
  18. Feldman SR. Misunderstandings. J Dermatolog Treat. 2007; 18(1):4.
    View in: PubMed
    Score: 0.264
  19. Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, Fleischer AB, Balkrishnan R, Feldman SR. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007 Feb; 56(2):211-6.
    View in: PubMed
    Score: 0.262
  20. Krejci-Manwaring J, McCarty MA, Camacho F, Carroll CL, Johnson K, Manuel J, Balkrishnan R, Hartle J, Fleischer A, Feldman SR. Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents. J Am Acad Dermatol. 2006 May; 54(5 Suppl):S235-6.
    View in: PubMed
    Score: 0.252
  21. Balkrishnan R, Camacho FT, Pearce DJ, Kulkarni AS, Spencer L, Fleischer AB, Feldman SR. Factors affecting prescription of ultra-high potency topical corticosteroids in skin disease: an analysis of US national practice data. J Drugs Dermatol. 2005 Nov-Dec; 4(6):699-706.
    View in: PubMed
    Score: 0.244
  22. Callender VD, Young CM, Haverstock CL, Carroll CL, Feldman SR. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis. Cutis. 2005 Jun; 75(6):317-21.
    View in: PubMed
    Score: 0.237
  23. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB, Feldman SR. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol. 2003 Jul; 49(1):79-82.
    View in: PubMed
    Score: 0.207
  24. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003; 4(4):221-4.
    View in: PubMed
    Score: 0.200
  25. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002 May; 41(5):269-74.
    View in: PubMed
    Score: 0.191
  26. Pona A, Haidari W, Kolli SS, Feldman SR. Diet and psoriasis. Dermatol Online J. 2019 Feb 15; 25(2).
    View in: PubMed
    Score: 0.153
  27. Oussedik E, Saleem MD, Feldman SR. A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation. J Drugs Dermatol. 2017 Oct 01; 16(10):972-975.
    View in: PubMed
    Score: 0.139
  28. Rajabi-Estarabadi A, Hasanzadeh H, Taheri A, Feldman SR, Firooz A. The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis. J Dermatolog Treat. 2018 Mar; 29(2):111-115.
    View in: PubMed
    Score: 0.137
  29. Sandoval LF, Huang KE, Harrison J, Clark A, Feldman SR. Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference. Cutis. 2014 Dec; 94(6):304-9.
    View in: PubMed
    Score: 0.114
  30. Feldman SR. Message from the guest editor. J Drugs Dermatol. 2012 Aug; 11(8):906.
    View in: PubMed
    Score: 0.097
  31. Kosari P, Feldman SR. Letter: Treatment-resistant pyoderma gangrenosum. Dermatol Online J. 2012 Apr 15; 18(4):8.
    View in: PubMed
    Score: 0.095
  32. Iaconi A, Feldman SR, Balkrishnan R. Psoriasis and its treatment with adalimumab. Expert Opin Biol Ther. 2010 Jan; 10(1):133-52.
    View in: PubMed
    Score: 0.081
  33. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009; 219(3):209-18.
    View in: PubMed
    Score: 0.079
  34. Yentzer BA, Yelverton CB, Simpson GL, Simpson JF, Hwang W, Balkrishnan R, Feldman SR. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J. 2009 Apr 15; 15(4):1.
    View in: PubMed
    Score: 0.077
  35. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008 Oct 02; 6:75.
    View in: PubMed
    Score: 0.075
  36. Pearce DJ, Thomas CG, Fleischer AB, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs. 2004 Oct; 16(5):421-8, 432.
    View in: PubMed
    Score: 0.056
  37. Ro T, Tull RZ, Cardwell LA, Farhangian ME, Moustafa F, Richardson I, Jorizzo JL, Feldman S, Huang W. A Pilot Study Characterizing Factors in Adherence to Cutaneous Lupus Treatment. J Cutan Med Surg. 2018 Sep/Oct; 22(5):530-532.
    View in: PubMed
    Score: 0.037
  38. Shaw MK, Davis SA, Feldman SR, Fleischer AB. Trends in systemic psoriasis treatment therapies from 1993 through 2010. J Drugs Dermatol. 2014 Aug; 13(8):917-20.
    View in: PubMed
    Score: 0.028
  39. Railan D, Wilson JK, Feldman SR, Fleischer AB. Pediatricians who prescribe clotrimazole-betamethasone diproprionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug's potency. Dermatol Online J. 2002 Oct; 8(2):3.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.